Elias Papatheodorou

Chief Executive Officer

Mr. Elias Papatheodorou brings with him more than 20 years of experience with private and public biotechnology companies, as well as with The Coca-Cola Company and Philip Morris International. As Chief Business Officer of Covagen AG, he was instrumental in the closing of a CHF46 million Series B financing round and the subsequent acquisition of Covagen by Jannsen Pharmaceuticals, a J&J Company. Previously, Elias was Senior Vice President for Operations and Business Development at Medigene AG. Elias has also served for a number of years as the CEO of Novosom AG. During his tenure, the Smarticles technology entered clinical trials in the U.S.A., the company raised funds and closed licensing deals. Finally, he engineered the sale of Novosom's assets to Marina Biotech (MRNA). He received his undergraduate education at Ithaca College, NY, and his graduate education at Cornell University, NY.

 

Hanna-Kaisa Borini

Finance Director

Hanna-Kaisa joined the company in October 2017. She has a degree in Economics and Business Administration and has previously worked at PwC as a Financial Auditor and at Gunvor as a Derivatives Controller. She has now oriented her career to the pharma/biotech industry with Genkyotex, starting as the Financial Controller and taking over the Finance Director position in June 2021.